[Evaluation of fluorescence in situ hybridization value in detection of chronic lymphocytic leukemia]

The aim of this study was to investigate the clinical value of fluorescence in situ hybridization (FISH) in detecting the genomic aberration of chronic lymphocytic leukemia (CLL). FISH was used for 32 patients who were newly diagnosed as CLL. Five types of fluorescence probes with labeled DNA probes were included as sequence specific probes D13S25 for 13q14.3, P53 for 17p13.1, ATM for 11q22.3, RB1 for 13q14 and chromosomes 12. Meanwhile, FISH was used to detect IGH/CCND1 fusion gene in 10 CLL patients with untypical immunophenotypes. The results showed that out of 32 patients, 26 cases (81.3%) were abnormal including 14 cases of D13S25 deletion, 11 of RB1 deletion, 9 of trisomia 12, 6 cases of P53 deletion, and 1 of ATM deletion. 12 cases showed 1 kind of genomic aberration, including 7 cases of trisomia 12, 3 cases of D13S25 deletion, 1 of P53 deletion, 1 of ATM deletion. 11 eases displayed 2 kinds of abnormalities. Out of 11 cases, 7 were D13S25/RB1 deletion, 4 were of P53 deletion, and 3 cases had 3 kinds of abnormalities. Among 10 patients with CD5(+)CD23(-), two were positive with IGH/CCND1. It is concluded that the FISH can improve the detecting of chromosomal abnormalities in CLL, and every abnormality has its special feature. Detection of IGH/CCND1 seems important in diagnoses of CLL.